Mochida Pharmaceutical Co., Ltd.

Equities

4534

JP3922800002

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-05-01 am EDT 5-day change 1st Jan Change
3,205 JPY +0.47% Intraday chart for Mochida Pharmaceutical Co., Ltd. +1.26% -1.99%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hidehiro Imatsu named president of Goldman Sachs Japan RE
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. CI
Mochida Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 15, 2023, has closed with 1,080,000 shares, representing 2.97% for ¥3,485.1 million. CI
Mochida Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2024 CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. CI
Mochida Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Dividend Guidance for the Year Ending March 31, 2024 CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. CI
Mochida Pharmaceutical Co., Ltd. Provides Second Quarter-End and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. CI
Mochida Pharmaceutical's Fiscal Full-Year Profit Falls 37.1% MT
Mochida Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
Mochida Pharmaceutical Co., Ltd. Provides Second Quarter-End and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Mochida Pharmaceutical Co., Ltd. Announces Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 30, 2023 CI
Mochida Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,080,000 shares, representing 2.96% for ¥3,500 million. CI
Mochida Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 1, 2022. CI
Mochida Pharmaceutical Co., Ltd.'s Equity Buyback announced on August 1, 2022, has closed with 1,036,200 shares, representing 2.78% for ¥3,499.72 million. CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 1, 2022. CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 1, 2022. CI
Mochida Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,190,000 shares, representing 3.17% for ¥3,500 million. CI
Mochida Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Chart Mochida Pharmaceutical Co., Ltd.
More charts
Mochida Pharmaceutical Co Ltd is a Japan-based company principally engaged in the production and sale of drugs. The Pharmaceutical-related segment is engaged in the manufacture, purchase and sale of pharmaceutical products. The Company also conducts brokerage and management of real estate properties, the maintenance and management of buildings, the agency of personal affairs, accounting and purchasing businesses. The Healthcare segment is involved in the manufacture, purchase and sale of quasi drugs and cosmetic products.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3,190 JPY
Average target price
3,200 JPY
Spread / Average Target
+0.31%
Consensus
  1. Stock Market
  2. Equities
  3. 4534 Stock
  4. News Mochida Pharmaceutical Co., Ltd.
  5. Mochida Pharmaceutical's Fiscal Full-Year Profit Falls 37.1%